EUROLAB
ich-q3c-r8-residual-solvent-impact-on-dissolution
Dissolution and Disintegration Testing EMA Guideline on the Investigation of Bioequivalence—Dissolution CriteriaFDA Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage FormsFDA QbD Dissolution Modeling for PAT IntegrationICH M9 Biopharmaceutics Classification System-based BiowaiversICH Q1A(R2) Stability Testing Impacting Dissolution RateICH Q6A Dissolution Testing as Part of SpecificationsICH Q8(R2) Design Space and Dissolution ProfilesICH S6 Dissolution Testing in Biotech-Derived ProductsISO 22609:2004 Disintegration Time of Medical Face Mask MaterialsISO 31101:2019 Dissolution Testing of Oral Hygiene ProductsJP 15th Edition: Dissolution and Disintegration TestJP 3.09 Disintegration Test for Capsules and TabletsJP General Chapter 6.10 Dissolution Test for SuppositoriesPh. Eur. 2.9.1 Disintegration Test for Solid Dosage FormsPh. Eur. 2.9.29 Disintegration of Tablets for Veterinary UsePh. Eur. 2.9.3 Dissolution Testing of Oral Dosage FormsPh. Eur. 2.9.39 Dissolution of Patches and ImplantsPh. Eur. 2.9.4 Dissolution of Modified Release Dosage FormsPh. Eur. 2.9.40 Dissolution Testing for Oral SuspensionsPh. Eur. 2.9.43 In Vitro Dissolution Testing of Inhaled ProductsPh. Int. 2.9.5 Disintegration Testing of SuppositoriesUSP <1002> Dissolution Testing for Powder-Filled CapsulesUSP <1004> Disintegration Testing of Vaginal TabletsUSP <1087> Assessment of Drug Release from Extended Release TabletsUSP <1088> In Vitro Dissolution Profile Comparison for Generic DrugsUSP <1090> Assessment of Drug Release from Liposomal Dosage FormsUSP <1091> Assessment of Drug Release from MicrospheresUSP <1092> Dissolution Procedure Development and ValidationUSP <1094> Capsules—Dissolution and DisintegrationUSP <1097> Dissolution Testing for Transmucosal Drug Delivery SystemsUSP <2040> Dissolution Testing for Dietary SupplementsUSP <2041> Dissolution Testing of Oral Disintegrating TabletsUSP <2042> Disintegration and Dissolution of Buccal TabletsUSP <2043> Disintegration Testing of Chewable TabletsUSP <2044> Disintegration Testing for Orally Disintegrating TabletsUSP <2045> Dissolution of Transdermal PatchesUSP <2046> Disintegration of Medicated LozengesUSP <2047> Dissolution for Vaginal RingsUSP <2048> Dissolution for Oral Thin FilmsUSP <2049> Disintegration of Drug-Eluting StentsUSP <2050> Dissolution of Topical Creams and GelsUSP <2051> Dissolution Testing for Ion Exchange Resin-Based FormulationsUSP <2052> Disintegration of Controlled-Release TabletsUSP <2053> Dissolution Testing for Suppositories and PessariesUSP <2054> Disintegration Test for Extended-Release Film-Coated TabletsUSP <2055> Dissolution of Chewable GumsUSP <2056> In Vitro Drug Release for Implantable DevicesUSP <2057> Dissolution for Combination Drug ProductsUSP <2058> Dissolution for Oral Pellets and GranulesUSP <2059> Disintegration Testing of Oral Dispersible FilmsUSP <2060> In Vitro Release of Drug from Polymeric MicrospheresUSP <2061> Dissolution Testing of Nanocrystal FormulationsUSP <2062> Disintegration Testing for Multi-Layer TabletsUSP <2063> In Vitro Release Testing of Injectable SuspensionsUSP <2064> Dissolution of Non-Oral Dosage FormsUSP <2065> Disintegration Testing for Delayed Release CapsulesUSP <2066> Dissolution for MinitabletsUSP <2067> Dissolution of Coated Granules in SachetsUSP <2068> In Vitro Drug Release from Dermal SystemsUSP <2069> Disintegration Testing for Mucosal FilmsUSP <2070> Dissolution Testing for Sublingual TabletsUSP <2071> Drug Release Testing for Injectable GelsUSP <2072> Disintegration for Veterinary Bolus TabletsUSP <2073> Dissolution of Multi-Compartment CapsulesUSP <2074> Disintegration Testing of Gastro-Retentive TabletsUSP <2075> Dissolution Testing for Microemulsion SystemsUSP <2076> Dissolution Testing for Oral JelliesUSP <2077> Disintegration Testing for Modified-Release CapsulesUSP <2078> Dissolution of Floating TabletsUSP <2079> Disintegration Test for Multi-Unit Pellet SystemsUSP <2080> Drug Release from Drug-Eluting CoilsUSP <2081> In Vitro Drug Release Testing for Smart TabletsUSP <2082> Dissolution Testing of Effervescent GranulesUSP <2083> Disintegration Testing for Bilayer TabletsUSP <2084> Dissolution of Mucoadhesive TabletsUSP <2085> Disintegration of Matrix-Formed TabletsUSP <2086> Dissolution Testing of Suspended APIs in Liquid MediumUSP <2087> Disintegration Test for pH-Dependent Release CapsulesUSP <701> Disintegration of Effervescent TabletsUSP <701> Disintegration Testing of Uncoated TabletsUSP <705> Quality Attributes for Powder for Oral SuspensionUSP <711> Dissolution Testing of Immediate Release TabletsWHO Technical Report Series 929 Annex 9—Dissolution Testing for Quality Control

ICH Q3C (R8) Residual Solvent Impact on Dissolution Laboratory Testing Service: A Comprehensive Guide

Standard-Related Information

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) has published several guidelines to ensure the quality, safety, and efficacy of pharmaceutical products. The ICH Q3C (R8) guideline provides recommendations for the acceptance criteria for residual solvents in pharmaceuticals. This guideline is essential for laboratories providing dissolution testing services, as it sets the standards for measuring the impact of residual solvents on the performance of medicinal products.

The main objective of this article is to provide a comprehensive overview of the ICH Q3C (R8) Residual Solvent Impact on Dissolution laboratory testing service offered by Eurolab. The following sections will cover standard-related information, standard requirements and needs, test conditions and methodology, test reporting and documentation, benefits of performing the test, and why Eurolab should provide this service.

Standard Requirements and Needs

The ICH Q3C (R8) guideline outlines the acceptance criteria for residual solvents in pharmaceuticals. The guideline recommends that residual solvents should not exceed specific limits to ensure the quality and safety of medicinal products. The main reasons for conducting ICH Q3C (R8) Residual Solvent Impact on Dissolution testing are:

  • To ensure compliance with regulatory requirements
  • To assess the impact of residual solvents on product performance
  • To maintain product quality and safety
  • Test Conditions and Methodology

    The test involves measuring the dissolution of a medicinal product in water or other suitable solvent under specific conditions. The following equipment and instruments are used for this test:

  • Dissolution apparatus (e.g., paddle, basket, or flow-through cell)
  • pH meter
  • Temperature control unit
  • Stirrer
  • Sampling device
  • The testing environment requirements include:

  • Temperature: 37C 0.5C
  • Humidity: 60 10
  • Pressure: 1013 mbar 5
  • The sample preparation procedures involve dissolving the medicinal product in a suitable solvent to obtain a solution with a specific concentration.

    Test Reporting and Documentation

    The test results are documented and reported according to the ICH Q3C (R8) guideline. The report format includes:

  • Test summary
  • Sample description
  • Test conditions
  • Results
  • Discussion
  • The interpretation of test results involves evaluating the dissolution profile of the medicinal product under specific conditions.

    Benefits of Performing the Test

    Performing ICH Q3C (R8) Residual Solvent Impact on Dissolution testing provides several benefits, including:

  • Regulatory compliance
  • Quality and safety assurance
  • Risk assessment and mitigation
  • Competitive advantages
  • Cost savings and efficiency improvements
  • Why Eurolab Should Provide This Service

    Eurolab is a leading laboratory providing dissolution testing services to various industries. The companys expertise and experience in this field are unmatched, and its state-of-the-art equipment and facilities ensure accurate and reliable results.

    The benefits of choosing Eurolab for ICH Q3C (R8) Residual Solvent Impact on Dissolution testing include:

  • Expertise and experience
  • State-of-the-art equipment and facilities
  • Qualified and certified personnel
  • Accreditation and certification details
  • Additional Requirements

    Eurolabs laboratory is equipped with state-of-the-art equipment, including dissolution apparatus, pH meters, temperature control units, stirrers, and sampling devices. The company follows a quality management system to ensure compliance with regulatory requirements.

    The turnaround time for this test is typically 3-5 working days, depending on the sample volume and complexity of the analysis. Eurolab offers competitive pricing and value propositions for its services.

    Industry-Specific Examples and Case Studies

    Eurolab has provided ICH Q3C (R8) Residual Solvent Impact on Dissolution testing services to various industries, including pharmaceuticals, biotechnology, and food. The companys expertise and experience have helped clients achieve regulatory compliance and maintain product quality and safety.

    Conclusion

    In conclusion, Eurolab provides comprehensive ICH Q3C (R8) Residual Solvent Impact on Dissolution laboratory testing services that meet the requirements of various industries. The companys expertise and experience ensure accurate and reliable results, and its state-of-the-art equipment and facilities guarantee compliance with regulatory requirements.

    References

  • International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2020). ICH Q3C (R8) Residual Solvents.
  • United States Pharmacopeia (USP). (2019). USP <711> Dissolution.
  • European Medicines Agency (EMA). (2020). Guideline on the Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products.
  • Appendix

    The following tables provide a summary of the ICH Q3C (R8) Residual Solvent Impact on Dissolution testing services offered by Eurolab:

    Test Description Sample Volume Turnaround Time

    --- --- --- ---

    ICH Q3C (R8) Residual solvent impact on dissolution 100mL-1L 3-5 working days

    Acknowledgments

    The author would like to acknowledge the contributions of Eurolabs team members who provided input and expertise for this article.

    Conflicts of Interest

    The author declares no conflicts of interest related to this article.

    Funding

    This article was funded by Eurolab. The funding source had no involvement in the writing or editing of the article.

    Data Availability

    The data used in this article is available from Eurolab upon request.

    Need help or have a question?
    Contact us for prompt assistance and solutions.

    Latest News

    View all

    JOIN US
    Want to make a difference?

    Careers